-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen ...
Latent cardiovascular toxicity issues continue to plague late-stage drug discovery efforts, as well as commercially launched pharmaceutical success. Many current in vitro models lack, or incompletely ...
SereNeuro Therapeutics, a preclinical biotechnology company developing non-opioid pain therapies, has unveiled new data on a ...
Investing.com - Leerink Partners has lowered its price target on Fate Therapeutics (NASDAQ:FATE) to $7.00 from $12.00 while maintaining an Outperform rating on the stock. The new target still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback